Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM Meeting Abstract
| Authors: | Lonial, S.; Richard, S.; Matous, J. V.; Yee, A. J.; Shah, U.; Mehta-Shah, N.; Martin, T.; Muchtar, E.; Ailawadhi, S.; Richardson, P. G.; Bhutani, M.; Perino, S.; Kirby, J.; Agafonov, R. V.; Chaturvedi, P.; Class, B.; Schnaderbeck, M.; Palmer, M. R.; Gorman, C.; Schoenborn-Kellenberger, O.; Hoerres, A.; Fisher, S. L.; Pollock, R. M.; Crystal, A.; Mahler, M.; Bardeja, J. |
| Abstract Title: | Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM |
| Meeting Title: | 113th Annual Meeting of the American Association for Cancer Research (AACR) |
| Journal Title: | Cancer Research |
| Volume: | 82 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2022 Apr 8-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-06-15 |
| Language: | English |
| ACCESSION: | WOS:000892509502106 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.AM2022-CT186 |
| Notes: | Meeting Abstract: CT186 -- Source: Wos |
